Corxel U.S
Corxel U.S. is a global clinical-stage biopharmaceutical company developing innovative oral medicines for obesity and related cardiometabolic conditions, with the goal of expanding access to effective, convenient, and scalable treatment options.
The company’s pipeline is led by CX11, an investigational, once-daily oral small-molecule GLP-1 receptor agonist that has demonstrated clinically meaningful weight loss and a generally favorable tolerability profile, and includes CX12, an investigational oral small-molecule amylin receptor agonist in preclinical development. Led by an experienced leadership team with expertise across clinical development, regulatory strategy and capital markets, Corxel U.S. is working to advance a differentiated cardiometabolic franchise for patients worldwide.
Corxel U.S. has global rights to CX11, excluding Greater China.
Our team
Kevin Xie, PhD
Dr. Kevin Xie serves as the Chief Financial Officer at CORXEL, where he oversees the company's capital strategy, financial operations, and investor relations.
With over 20 years of experience in healthcare investment and operations, Kevin brings a wealth of expertise and leadership to the organization. Most recently, Kevin served as the Chief Financial Officer of Gracell Biotechnologies, beginning in July 2020. During his tenure, he played a pivotal role in several landmark achievements, including the company's crossover financing in 2020, its Nasdaq IPO in 2021, a subsequent secondary equity PIPE financing in 2023, and Gracell's eventual acquisition by AstraZeneca in 2024. In addition, Kevin also oversaw Gracell's U.S. non-clinical operations. Prior to joining Gracell, Kevin was the President of Healthcare Holdings for Fosun Group and Chief Representative of Fosun NY from 2015 to 2020. In this role, he led Fosun Group's global healthcare investment initiatives. Before Fosun, Kevin spent over a decade in senior management positions at several prominent healthcare investment firms in the United States. He co-founded Locust Walk Capital, served as Healthcare Sector Head at Scopia Capital, and was a Managing Director at Great Point Partners. In addition to his executive roles, Kevin has served on the boards of directors of multiple publicly traded companies.
Kevin holds an MBA from The Wharton School at the University of Pennsylvania and a Ph.D. in Chemistry from the City University of New York.
Bo Liang, MD, PhD
Dr. Bo Liang, MD, serves as the Chief Medical Officer at CORXEL. Bo is responsible for accelerating our pipeline of metabolic therapies and the overall development and execution of global clinical programs, advancing CORXEL’s growing assets and portfolio with the objective of gaining broad regulatory approvals and market authorizations across the world. He is based in Denmark.
Before joining CORXEL, Bo was the Senior Vice President of Clinical Development (Metabolic Therapy Area) at Hengrui Pharmaceuticals. In this role, he was responsible for global development strategies and execution in the fields of diabetes, obesity, MASH (Metabolic Associated Steatohepatitis), and other metabolic related areas. Prior to this, he served as the Senior Director and Acting Vice President at Novo Nordisk A/S, where he was responsible for therapeutic area strategies and execution in the diabetes field. He led and participated in the global clinical development and regulatory submissions of innovative treatments such as Icodec (the first once weekly insulin formulation), Semaglutide (once weekly GLP-1 RA), and the IcoSema fixed-dose combination.
Bo graduated with a Medical Doctor (MD) degree from Tongji University and eared his PhD at the Faculty of Health Science at the University of Copenhagen in Denmark. He was appointed as an Associate Professor at the University of Copenhagen in 2013, where he engaged in research on the pathogenesis of arrhythmias and the development of new drugs.
